The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear¥1,529.32Fair value¥3,889.31Bull¥6,873.03
FairClose
52-week traded range
52W low ¥1,879.0052W high ¥2,400.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
ZERIA PHARMACEUTICAL CO.,LTD. closed at ¥1,982.00, 49.0% below the consensus fair value of ¥3,889.31 drawn from 9 valuation models.
Financial DNA score 71/100 — Strong. P/E of 10.3x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
¥3,419.83
+72.5%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
¥3,249.56
+64.0%
√(22.5 × EPS × BVPS)
EPS=191.8, BVPS=2446.91
P/E Fair Value
¥3,836.00
+93.5%
EPS × 20x (sector P/E)
EPS=191.8, Sector P/E=20x
Peter Lynch (PEG)
¥4,002.87
+102.0%
EPS × Growth% (PEG = 1 is fair)
EPS=191.8, g=20.9%
EV/EBITDA
¥6,873.03
+246.8%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=19B
Dividend Discount (DDM)
¥2,643.59
+33.4%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=48.96, r=10%, g=8%
Book Value (P/B)
¥1,529.32
-22.8%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=2446.91, ROE=8.5%, g=6%, r=10%
Reverse DCF
¥1,982.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -1.9% | Historical: 20.9%
Margin of Safety
¥2,626.35
+32.5%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=3501.8, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.